Sarepta Therapeutics
The Patient Engagement Liaison at Sarepta is responsible for supporting families affected by Duchenne Muscular Dystrophy during their treatment consideration phase with educational resources, support, and community connections. They act as a trusted point of contact, facilitating informed decisions and connecting families to relevant programs and services.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Sarepta Therapeutics.
Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade
2 weeks ago
Senior Medical Science Liaison - DMD/Neuromuscular (South)
Regenxbio
AD, Patient & Community Liaison - Central US Region
lifelancer
AD, Patient & Community Liaison Northeast - REMOTE
Novartis
Visiting Research Scholar
Wright State University
Senior Medical Science Liaison - DMD/Neuromuscular (South)
REGENXBIO Inc
Senior Director, Medical Information
Dyne Therapeutics